Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5698_Библиотеки_им_академика_М_И_Перельмана
.pdf
quantify the stability study’s numerous time points. The stability study of the phyto-
pharmaceutical, on the other hand, necessitates the simultaneous estimate and quantifi-
cation of many markers.
• Possibility of chemical reactions among phytoconstituents: During a stability study,
exposing phytopharmaceuticals to a variety of environmental conditions such as light,
temperature, humidity, air, etc., may cause chemical reactions between or among its
multiple chemical constituents, resulting in changes in the levels of constituent(s)
responsible for one or more activities. As a result, chemical markers whose levels can be
linked to specific or numerous biological processes are needed. During stability tests of
phytopharmaceutical, this can be accomplished by closely monitoring the fingerprint
profiles and the biological activity of stability samples compared to the control sample.
• Enzymatic activities during shelf life: Plant secondary metabolites make up most of
the chemical ingredients in an herbal remedy or product. The coordinated activities of
numerous enzymes belonging to the categories of hydrolases, transferases, ligases, oxi-
doreductases, isomerases, and lyases control their quantities in plants. Conjugation pro-
cesses, interconversion reactions, oxidative polymerization, and degradative reactions
are all catalyzed by these enzymes. Feedback mechanisms regulate enzyme activity dur-
ing the pre-harvest period. Chlorophyllase, catalase, ascorbate oxidase, peroxidase,
esterase, pectin, polygalacturonase, galactosidase, phospholipase, and lipoxygenase are
few examples of postharvest active enzymes that continue to act during plant storage
and cause changes in the chemical composition of the herbal substance or product. As a
result, enzymes may play an essential role in affecting the stability and shelf life of phy-
topharmaceuticals. As a result, to analyze the impact of enzyme activity on phytophar-
maceutical shelf life, it is advised that enzymes with a high probability of being active
during the post-harvesting period be identified using appropriate enzyme assays.
Furthermore, throughout the stability study, their biochemical roles and levels should
be monitored using particular enzyme assays and specific substrate(s) or product(s) dur-
ing the shelf life .
4.2 Stability study
The purpose of a stability study is to determine how the quality of phytopharmaceutical
changes over time due to various deteriorating environmental factors such as temperature,
humidity, and light, as well as to predict the shelf life (expiry date) and suggest proper stor-
age conditions. The shelf life is the amount of time it takes for the initial concentration to
reach 90%. If maintained correctly under prescribed storage circumstances, a product main-
tains acceptable physical, chemical, and microbiological stability throughout its shelf life. The
Arrhenius equation, which explains the influence of temperature (T) on the rate constant
(k) of a chemical process, is used to predict shelf life:
k ¼ Ae
eEa
=
RT
where “A” stands for the frequency factor or Arrhenius factor, “Ea” stands for the energy
of activation, “R” stands for the universal gas constant, and “T” stands for the absolute
9. Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products238
https://t.me/med1917
thermodynamic temperature. The frequency of molecular collisions between molecules is
known as the Arrhenius factor.
Currently, two recommendations, the ICH and WHO guidelines, provide sufficient infor-
mation for conducting a finished product stabilit y analysis. Such research is typically con-
ducted on the final dose form and packaging in which the drug is prescribed for
commercialization [14,51].
4.2.1 Interactions issues
The current usage of herbal medicine is ubiquitous, but society faces a dilemma in deter-
mining whether a patient would disclose to his or her medical practitioner that he or she is
using herbal products in addition to conventional pharmacotherapy. Some observational
studies have revealed adverse or contradictory drug-herb interactions, even though herb-
drug interactions might theoretically be good or neutral. Herbal medications typical ly contain
many pharmacologically active substances, which increases the chances of interactions signif-
icantly. Herb-drug interactions are more likely to occur than drug-drug interactions in many
cases. The pharmacokinetic herb-drug interactions are induced by one drug interacting with
another drug’s elimination, metabolism, distribution, or absorption. The pharmacodynamic
herb-drug interactions caused by two different drugs functioning in the same or opposite di-
rections can increase or decrease the pharmacological or toxicological effects. For example, St.
John’s Wort, a well-known cytochrome P450 inducer, has been shown to impact the systemic
bioavailability of numerous conventional medicines. Typical cases of herb-drug interactions
have been discovered when cardiovascular drugs with a limited therapeutic index, such as
digoxin and warfarin, are coadministered with herbs. Concurrent use of warfarin with St.
John’s Wort, for example, lowers prothrombin time, resulting in a reduced anticoagulant ac-
tion and the requirement for a higher warfarin dose (Fig. 9.3). St. John’s Wort with cyclo-
sporine and grapefruit juice with felodipine and lovastatin are two further examples of
interactions [52,53].
The existing evidence that herbal medicine interacts with conventional medications is
based primarily on patient case reports, case series, and a small number of clinical investiga-
tions. Drug-herbal interaction evaluation challenges include.
• Lack of compositional reliability of herbal products and a variety of interactions,
including drug-metabolizing enzymes and drug transporter systems, as well as pharma-
codynamic interactions.
• Phytopharmaceuticals’ pharmacokinetic and pharmacodynamic properties are not well
understood.
Zhu et al. reported that rutaecarpine, an alkaloid found in Evodia rutaecarpa, had significant
effects on hepatic drug processing enzyme gene expression, CYP enzyme genes, and UDP-
glucuronosyltransferase, as well as increased the expression of hepatic uptake and efflux
transporters. These effects could have a combined role in the enhanced metabolism and elim-
ination of acetaminophen, caffeine, and theophylline due to rutaecarpine [54].
The pharmacokinetic interactions between allopathic medications, phytopharmaceuticals,
and dietary products in the body are mediated by biotransformation enzymes and membrane
transporter proteins. The principal sources of such interactions are cytochrome P450 (CYP) iso-
enzymes (CYP isomers such as CYP2C9, 2D6, 2E1, 3A4, and 1A2) and P-glycoprotein (P-gp).
4. Storage and stability issues 239
https://t.me/med1917
Many phytopharmaceutical components may have an impact on the pharmacokinetic and
pharmacodynamic properties of herbal preparations. In vitro screening assays and clinical in-
vestigations may be required to discover potential drug interactions due to potential medica-
tion interactions, particularly for phytopharmaceuticals with a restricted therapeutic index.
Although medication interaction studies are not typically included in a general toxicity test
battery, they can be used to uncover potential concerns in specific patient groups. Garlic or
ginkgo, for example, may increase clotting times and so interact with antiplatelet medications
like aspirin or warfarin, increasing the risk of life-threatening bleeding. Despite the availability
of causality evaluation tools, diagnosing herbal-drug-induced hepatotoxicity remains difficult.
Even though herbal drugs have been used for millennia, there are only a few clinical trials in
the literature. As a result, postmarket pharmacovigilance is a valuable source of safety data,
and causality analysis reveals a link between an observed adverse event and a suspected phy-
topharmaceutical. Although no universally acknowledged method for determining causality
exists, current methods rely on algorithmic, probability-based, and expert evaluations, as
well as the quality of adverse reaction reports. Narrative descriptions of herbal adverse re-
sponses are less compelling until causality is demonstrated [55].
FIGURE 9.3 Generalized mechanistic insight into herb-drug interactions.
9. Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products240
https://t.me/med1917
4.3 Exointeractions and endointeractions theory
Endointeractions are those interactions which occur between substances present within the
extract while exointeractions are those interactions with substances not present in the extract.
Both endointeractions and exointeractions may have a significant effect on human health.
Phytochemical interactions may explain the inconsistent performance of dietary supplements
undesirable side effects of drugs and the health effects of regional diets (like sub Sahara).
Endointeractions have already been verified in b-carotene, tomatoes (lycopene), St. John’s
Wort (hypericin, hyperforin), soy (isoflavones), cranberries (flavonoids), and broccoli (sulfo-
raphane), just to name a few [56].
In our opinion, many researches needed on these contentious and unresolved areas (crude
vs. single plant extracts) may augment the activity of existing pharmaceutical preparations,
and may perk up the effectiveness of existing herbal remedies for use in isolated geographical
areas where modern drugs are unavailable.
5. Regulatory aspects
The legal status of phytopharmaceuticals differs from one jurisdiction to the next. Phyto-
pharmaceuticals are well-established in some countries, yet they are considered food in
others, and medicinal claims are not permitted. On the other hand, developing countries
frequently have a large number of traditionally used natural products and a considerable
deal of folk knowledge about them, but few regulatory criteria for including these tradition-
ally used herbal remedies in drug regulation. The following elements are used in regulatory
systems to classify herbal or traditional medical products: description in a pharmacopeia
monograph, prescription status, claim of a therapeutic effect, scheduled or regulated compo-
nents or substances, or durations of use. Some countries distinguish between “officially
approved” and “officially recognized” items, the latter of which can be promoted without
the authority’s scientific approval [57,58]. Some of the commonly faced regulatory challenges
[57,58] are.
• Improper product categorization: It is critical to distinguish between medicinal prod-
ucts and herbal dietary supplements to implement appropriate regulatory controls to
ensure their purity, safety, and efficacy. Precise product categorization will aid in deter-
mining the appropriate amount of regulatory oversight. Countries can regulate herbal
items like food or therapeutic products, depending on their legislation and definitions.
The regulatory requirements for food are usually less stringent than those for pharma-
ceuticals. Food should regulate products that do not make claims to control, prevent, or
treat diseases. When garlic is sold as a spice, it is controlled as a portion of food; but,
when it is claimed to lower blood cholesterol levels, it is considered as
phytopharmaceuticals.
• Regulatory variation: Phytopharmaceuticals are regulated differently in each country,
with varying levels of oversight. Herbal products, for example, are often classified as di-
etary supplements in the United States and hence are subject to less strict regulatory
oversight than conventional therapies. On the other hand, herbal products are classified
5. Regulatory aspects 241
https://t.me/med1917
as medicinal items in China and are therefore subject to the same level of regulatory
oversight as conventional treatments. Regulatory regulation needs to be harmonized to
facilitate the international movement of phytopharmaceuticals from one country to
another.
• Regulation of premarket and postmarket control variation: Regulatory authorities use
a two-tier control approach, including premarket and postmarket oversight. Herbal
products are surveyed before being placed on the market under premarket control, and
final herbal goods are regularly examined and surveyed after being placed on the mar-
ket under postmarket control. In comparison to raw plants, finished herbal compositions
are more strictly regulated. As a result, both premarket and postmarket control requires
the same amount of regulation. Table 9.1 shows countrywide legal status of herbal
drugs.
5.1 Regulatory aspects on stability study of herbal products
Medicine regulatory agencies such as the European Medicines Agency (EMEA), the Inter-
national Conference on Harmonization (ICH), and the World Health Organization (WHO) all
demand stability data before approving a drug. Section 17.4 of the WHO Supplementary
Guidelines for the Manufacturing of Herbal Medicinal Products is dedicated to this topic.
This explicitly indicates that if an herbal ingredient or herbal preparation has an expiry
date, stability evidence must be provided to support the projected shelf life of finished herbal
products under the stated storage circumstances. Stability data is always required to support
the completed herbal product’s shelf life [59]. The EMEA has also issued a set of quality
guidelines for herbal medicinal products, which state that because the herbal substance or
herbal medicinal product in its entirety is considered the active substance, determining the
stability of constituents with known therapeutic activity will not suffice. Other phytoconstitu-
ents contained in the herbal substance or herbal product should, to the extent practicable, be
assessed as well, e.g., using appropriate fingerprint chromatograms. It should also be shown
that their proportional content is comparable to that of the original fingerprint [60].
Assay of indicators (active or analytical), biological evaluations, chromatographic chemo-
profiling, or fingerprinting under various stability settings are some methods used to forecast
shelf life. These parameters are primarily agreed upon in several international and country-
specific guidelines on herbal product quality.
The stability data of phytopharmaceutical drugs should be assessed by storing them at
40.2
C and humidity at 75% RH 5% RH for 0, 1, 2, 3, and 6 months, according to phytophar-
maceutical guidelines. The stability data of a phytopharmaceuticals medicine in dosage form
or formulation placed in the pack intended for marketing can be estimated by storing the
formulation at 40.2
C and hum idity at 75% RH 5% RH for 0, 1, 2, 3, and 6 months.
Stability Determination: The goal of stability research is to evaluate a drug’sefficacy, give
background information throughout the product or drug discovery development phase, and
produce appropriate packag ing information for the quality, strength, purity, and integrity of
a produ ct during its shelf life. The basis of the stability study premise is the examination of
the active agent or final formulation under a variety of environmental conditions such as tem-
perature, humidity, and light. Various stability-indicating parameters, such as loss of thera-
peutic activity, change inactive component amount, change inactive component
9. Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products242
https://t.me/med1917
TABLE 9.1 Countrywise legal status of herbal drugs.
Country Legal status
South Africa The sale of unprocessed indigenous herbal products is uncontrolled. However, once a finished
product makes a health-related claim, it must go through the entire drug evaluation process at the
Medicines Control Council (MCC) before being marketed.
Argentina A laboratory is often required for the marketing authorization of a new pharmaceutical products and
compliance with the legislative requirements of article 27 of Law No. 16.463. There is no distinction
between herbal and chemical treatments. Such a monograph can be referred to when the active
principle is described in the Pharmacopeia Nacional Argentina. If not, a “Pre-monografia” must be
submitted to the Instituto Nacional de Farmacologia y Bromatologia, which is in charge of
pharmaceuticals and food, for permission.
Canada Herbal medicines are regulated as medications in Canada; therefore, they must comply with the food
and drugs Act and regulations regarding labelling and other standards. This means that, unlike in the
United States, many herbal medicines with indication claims are legally available in Canada. The
content and labelling of medicine must be scrutinized before registration, or a drug identification
number can be assigned.
USA Since then, the Food and Drug Administration (FDA) has regulated any goods that claim to treat, cure,
alleviate, or prevent disease as medications. As a result, if any herbal medicine claims are to be
authorized, the same procedures for a chemical drug must be followed. Even though many natural
products are utilized as folk medicines in the United States, they are controlled as foods or food
additives.
Saudi Arabia The Ministry of Health requires that pharmaceutical items be registered.
Finland Raw materials must meet pharmacopeia standards or, if none exist, comprehensive quality
requirements must be written per the model of the European Pharmacopeia monographs. Quality
requirements for intermediate and completed goods must be supplied, with the latter including, for
example, active component identification and determination using validated methods, as well as a
purity test. If the product contains more than one herbal treatment, the TLC fingerprint method
should identify them all.
Germany Herbal medications are regarded to be full-fledged medicines.
Bibliographic evidence of herbal medicine’s well-established use is recognized.
Italy Herbal products that make therapeutic claims have a specific pharmacological activity or are
potentially harmful are classified as medicines and can only be marketed through pharmacies. Herbal
mixtures, such as herbal teas or similar preparations, must be registered as medicinal products with a
brand name and therapeutic indications. Only a pharmacist is permitted to sell them in a pharmacy.
India The Drugs and Cosmetics Act of 1940 and the Drugs and Cosmetics Rules of 1945 govern traditional
remedies.
Thailand There are no restrictions on the production and sale of medical plants as long as they are sold as such.
However, distributors are required by law to acquire clearance from the Food and Drug
Administration before mixing or putting medicinal plants into dosage forms.
China Herbal medicines are typically classified as medicinal products, which require additional marketing
criteria such as a quality dossier, safety and efficacy evaluations, and special labelling. According to
the Drug Administration Law, new medications must be evaluated and approved. An approval
number is assigned to a new drug certificate after it has been approved. The factory is subsequently
permitted to sell the goods.
Japan New Kampo medications are regulated in much the same way as Western drugs. They are considered
a type of combination medication, and the NDA requires the exact data for new Kampo
pharmaceuticals as it does for new Western drugs.
Vietnam The Viet Nam Pharmacopeia, which includes national standards for 215 plants commonly used in
traditional medicine and 27 indigenous medicines made from medicinal plants, was issued by the Viet
Nam Committee for the Pharmacopeia to ensure the quality and therapeutic efficacy of herbal
pharmaceuticals.
https://t.me/med1917
physicochemical property, change in product bioavailability, loss of content uniformity, loss
of elegance, change in physical properties (density, viscosity, consistency, etc.), formation of
toxic degradation products, and drug pol Hydrolysis, oxidation (particularly in volatile,
fixed, and essential oils), racemization, geometric isomerization, and polymerization are all
chemical changes in herbal formulations that can be predicted.
5.2 General methods of stability assessment
Herbal formulation’s stability may be determined based on physical, sensory tests, micro-
bial tests, chemical tests, therapeutic efficacy tests, and safety tests [14].
• Physical and Sensory Tests: Physical changes in herbal formulations are familiar when
they are stored. Physical changes are primarily qualitative and are utilized as a reference
for observing preliminary stability. Changes in physical attributes indicate degradation
and instability of the completed herbal product.
Some of the physical attributes, such as changes in optical clarity, taste, color, odor, phase
behavior (flocculation, coalescence, cracking, creaming, etc.) in case of suspension/emulsion,
total solid content, specific gravity, refractive index, hardness, conductivity, turbidity, globule
size, zeta potential, polydispers ity index (PDI), viscosity, moisture content, porosity, flow
property of a powdered product, disintegration time, capping, lamination, layering in case
of a tablet, crystallization of amorphous substances, transitions in crystalline states, spread-
ability, occlusivity, and syneresis in case of gel or semisolid formulations were generally eval-
uated for stability purpose.
• Microbial Tests: When a product is contaminated with bacteria, it becomes unstable
and dangerous. As a result, microbiological contamination, a limit, or a load test should
be performed on the completed herbal product. The amount of live bacteria present in
the herbal raw material and finished formulation is determined using a microbiological
limit test. Preservatives are commonly utilized to protect the completed herbal product
from microbial contamination or growth during storage and usage. The efficacy of the
preservative is highly influenced by factors such as the active ingredient ’ s composition,
formulation excipients, storage conditions, the container, and its closure. As a result,
preservative efficacy or challenge tests of the completed herbal formulation (when pre-
servatives are used) are necessary to determine the product’s stability and shelf life [57].
Herbal medical goods in category “A” contain herbal drugs, with or without excipients,
and are intended to manufacture infusions and decoctions with boiling water (for example,
herbal teas, with or without added flavorings). Herbal medicinal products including ex-
tracts and herbal medications, with or without excipients, in which the method of process-
ing (for example, extraction) or , if appropriate, in the case of herbal pharmaceuticals,
pretreatment reduces the levels of organisms to below those stated for category B. Category
“C” refers to herbal medicinal products that contain extracts and herbal drugs, with or
without excipients, and where it can be demonstrated that the method of processing (for
example, extraction with low strength ethanol or nonboiling or low-temperature water)
or, in the case of herbal drugs, pretreatment, would not reduce the level of organisms suf-
ficiently to prevent regrowth [14].
9. Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products244
https://t.me/med1917
Various environmental conditions changed the chemical constitution of phytoconstituents
during the storage of herbal goods. Other unstable constituents may replace the phytocon-
stituents. Due to incompatibility with formulation excipients or with the container or closure
mechanism, new compounds may develop. Under the influence of temperature, humidity,
and light during manufacture, shipping, and storage, phytoconstituents from various chem-
ical classes in an herbal formulation may undergo a variety of intermolecular or intramolec-
ular reactions. As a result of these interactions, goods may beco me less or more active and
hazardous [47]. Polyphenols, for example, form reversible complexes with polysaccharides
and proteins through H-bonding and hydrophobic interactions, resulting in a decrease in
free polyphenol levels. Noncovalent interactions improve the water solubility of tannins in
the presence of water-soluble glycosides, as seen with paeoniflorin and glycyrrhizin. In the
presence of tannins, alkaloids tend to precipitate. Heavy metal ions produce monodentate
and bidentate complexes with polysaccharides, tannins, and lignins. Such phytochemical in-
teractions lead a herbal product’s chemical profile to change during storage, potentially
affecting or altering its therapeutic effectiveness [47,56,61].
Safety and Toxicity Parameters Test: The physicochemical properties of phytoconstitu-
ents in an herbal product are altered due to the action of external variables (light, humidity,
temperature, air, microorganisms). Toxic adducts may occur as a result of this. As a result,
safety testing at various stages of stability research is critical. For medicines used in treati ng
acute disorders, the acute toxicity of the herbal formulation can be measured at the start and
end of the stability study. Subchronic and chronic toxicity studies may be conducted [14]. In
the case of medicinal plants, legislative controls have not emerged around a structured con-
trol paradigm. Governments identify medical plants, herbs, and products derived from them
in various ways, and countries have tak en various measures for licensing, dispensing,
manufacturing, and trading to ensure their safety, quality, and efficacy [58].
6. Concluding remarks and future prospects
The positive results of phytopharmaceuticals open up new avenues for pharmacotherapy
and new options for pharmaceutical companies. The new phytopharmaceutical products can
be commercialized as a new chemical-based entity after receiving NDA approval from
CDSCO. Strict restrictions and in-depth research, on the other hand, will help achieve goals
more effectively.
There is also a pressing need for scientific evidence of the pharmacological properties and
safety of herbal remedies, which have been used in many countries for millennia as tradi-
tional medicines. This is especially important since clinical risk assessment requires a thor-
ough understanding of the mechanisms of action and interactions. Furthermore, the
development of an appropriate postmarket pharmacovigilance system will aid in the preven-
tion of phytopharmaceutical fatalities. Surveillance for adverse reactions to phytopharma-
ceuticals should primarily motivate voluntary reporting from consumers and healthcare
providers. Establishing a national and regional database to track the usage of phytopharma-
ceuticals might be beneficial. Efforts should also be made to educate healthcare providers and
patients on the use of phytopharmaceuticals.
6. Concluding remarks and future prospects 245
https://t.me/med1917
To ensure the safety and therapeutic efficacy of herbal medicine products, researchers
must look at the effects of storage conditions on their physicochemical stability and their ther-
apeutic activity, toxicity, and microbiological contamination. As a result, during systematic
stability investigations, physical and chemical stability and significant therapeutic actions
of an herbal substance/product must be evaluated. Enzymes that are suspected of being
active after harvesting should also be identified. Testing and monitoring of their activities
could become a crucial part of the stability study protocols. Furthermore, research efforts
should be focused on identifying markers in herbal substances/products whose levels can
be linked to the herbal substance/desired product’s therapeutic efficacy(ies). The long-term
techniques sugge sted above could undoubtedly aid in addressing the toxicological concerns
about herbal medications in emerging nations.
Healthcare professionals should be aware of herb-drug inter actions and encourage pa-
tients to discuss phytopharmaceutical use, to improve communication between patients
and physicians about phytopharmaceutical use, and physicians should question patients
about their use of phytopharmaceuticals. Meanwhile, more preclinical and clinical research
is needed to determine herb-drug interactions, and government regulatory agencies should
focus more on natural health prod uct laws.
References
[1] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981
to 09/2019. Journal of Natural Products 2020;83(3):770e803. https://doi.org/10.1021/acs.jnatprod.9b01285.
[2] Zhang B, Peng Y, Zhang Z, Liu H, Qi Y, Liu S, et al. GAP production of TCM herbs in China. Planta Medica
2010;76(17):1948e55. https://doi.org/10.1055/s-0030-1250527.
[3] Raina MK. Quality control of herbal and herbo-mineral formulations. Indian Journal of Natural Products
2003;19:11e5.
[4] Mukherjee PK. Quality control of herbal drugs: an approach to evaluation of botanicals. Business Horizons.
2002.
[5] Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. Heavy metal content of Ayurvedic herb-
al medicine products. Journal of the American Medical Association 2004;292(23):2868e73. https://doi.org/
10.1001/jama.292.23.2868.
[6] De Smet PAGM. Herbal remedies. New England Journal of Medicine 2002;347(25):2046e56. https://doi.org/
10.1056/NEJMra020398.
[7] Shinde V, Dhalwal K, Mahadik K. Some issues related to pharmacognosy. Pharmacognosy Reviews 2008;2(3).
[8] Patwardhan B. Ayurveda: the “Designer” medicine: a review of ethnopharmacology and bioprospecting
research. Indian Drugs 2000;37(5):213e27. https://www.indiandrugsonline.org/.
[9] Lieberman. Pharmaceutical dosage forms, tablets, vol. 1; 1980.
[10] Tong HHY, Wong SYS, Law MWL, Chu KKW, Chow AHL. Anti-hygroscopic effect of dextrans in herbal for-
mulations. International Journal of Pharmaceutics 2008;363(1e2):99e105. https://doi.org/10.1016/
j.ijpharm.2008.07.016.
[11] Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a Ma huang-
containing drink. Journal of Clinical Psychopharmacology 1997;17(5):437e9. https://doi.org/10.1097/
00004714-199710000-00025.
[12] Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary
supplements containing ephedra alkaloids. New England Journal of Medicine 2000;343(25):1833e8. https://
doi.org/10.1056/NEJM200012213432502.
[13] Neergheen-Bhujun VS. Underestimating the toxicological challenges associated with the use of herbal medicinal
products in developing countries. BioMed Research International 2013;2013. https://doi.org/10.1155/2013/
804086.
9. Phytopharmaceuticals and herbal drugs: prospects and safety issues in the delivery of natural products246
https://t.me/med1917
[14] Kumadoh DORIS, Ofori-Kwakye KWABENA. Dosage forms of herbal medicinal products and their stability
considerations-an overview. Journal of Critical Reviews 2017;4:1e8.
[15] Regulatory situation of herbal medicines: a worldwide review (who.int). (n.d.).
[16] Schilter B, Andersson C, Anton R, Constable A, Kleiner J, O’Brien J, et al. Guidance for the safety assessment of
botanicals and botanical preparations for use in food and food supplements. Food and Chemical Toxicology
2003;41(12):1625e49. https://doi.org/10.1016/S0278-6915(03)00221-7.
[17] WHO guidelinesforassessingqualityofherbalmedicineswithreferenceto contaminantsandresidues. (2007).World
Health Organization. Available from: https://apps.who.int/medicinedocs/documents/s14878e/s14878e.pdf.
[18] OECD. The OECD guidelines for the testing of chemicals: 420. Acute oral toxicity e fixed dose procedure. 2001.
[19] OECD. The OECD guidelines for the testing of chemicals: 423. Acute oral toxicity e acute toxic class method.
2001.
[20] OECD. The OECD guidelines for the testing of chemicals: 425. Acute oral toxicity e up-and-down-procedure
(UDP). 2008.
[21] Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, et al. A European pharmaceutical company
initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Regulatory Toxicology and Pharmacology 2008;50(3):345e52. https://doi.org/10.1016/j.yrtph.2007.11.009.
[22] OECD. The OECD guidelines for the testing of chemicals: 407. Repeated dose 28-day oral toxicity study in ro-
dents. 2008.
[23] Hartmann E, Strauss V, Eiben R, Freyberger A, Kaufmann W, Loof I, et al. ESTP comments on the draft updated
OECD test guideline 407. Experimental & Toxicologic Pathology 2008;59(5):297e300. https://doi.org/10.1016/
j.etp.2007.10.007.
[24] OECD. The OECD guidelines for the testing of chemicals: 452. Chronic toxicity studies. 2009.
[25] Svensson BM, Mathiasson L, Mårtensson L, Bergström S. Artemia salina as test organism for assessment of acute
toxicity of leachate water from landfills. Environmental Monitoring and Assessment 2005;102(1e3):309e21.
https://doi.org/10.1007/s10661-005-6029-z.
[26] Wiesner J. Challenges of safety evaluation. Journal of Ethnopharmacology 2014;158:467e70. https://doi.org/
10.1016/j.jep.2014.08.013.
[27] OECD. The OECD guidelines for the testing of chemicals: 471. Bacterial reverse mutation test. 1997.
[28] Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, et al. Strategy for genotoxicity
testing: hazard identification and risk assessment in relation to in vitro testing. Mutation Research, Genetic Toxi-
cology and Environmental Mutagenesis 2007;627(1):41e58. https://doi.org/10.1016/j.mrgentox.2006.10.003.
[29] OECD. The OECD guidelines for the testing of chemicals: 475. Mammalian bone marrow chromosome aberra-
tion test. 2014.
[30] OECD. The OECD guidelines for the testing of chemicals: 487. In vitro mammalian cell micronucleus test
(MNvit). 2014.
[31] OECD. The OECD guidelines for the testing of chemicals: 476. In vitro mammalian cell gene mutation tests using
the Hprt and xprt genes. 2015.
[32] OECD. The OECD guidelines for the testing of chemicals: 422. Combined repeated dose toxicity study with the
reproduction/developmental toxicity screening test. 2015.
[33] OECD. The OECD guidelines for the testing of chemicals: 451. Carcinogenicity studies. 2009.
[34] Atul Bhattaram V, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal
medicinal products. Phytomedicine 2002;9(3):1e33. https://doi.org/10.1078/1433-187X-00210.
[35] Guidance I. Guidance for industry S8: immunotoxicity studies for human pharmaceuticals. 2006.
[36] Pugsley MK, Authier S, Curtis MJ. Principles of safety pharmacology. British Journal of Pharmacology
2008;154(7):1382e99. https://doi.org/10.1038/bjp.2008.280.
[37] Sahu AN, Mohapatra D. (n.d.). Herbal drug formulation and standardization (pp. 978e993).
[38] Lachman L, Lieberman HA, Khar RK, Vyas SP, Farhan AJ, Jain JK. The theory and practice of industrial phar-
macy, vol. 245. CBS Publishers and Distributors Pvt. Ltd; 2013.
[39] Wang W, Sun C, Mao L, Ma P, Liu F, Yang J, et al. The biological activities, chemical stability, metabolism and
delivery systems of quercetin: a review. Trends in Food Science & Technology 2016;56:21e38. https://doi.org/
10.1016/j.tifs.2016.07.004.
[40] Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Alternative Medicine Review
2011;16(3):239e49.
References 247
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана